Nahdi Medical Company, the largest pharmacy retailer in Saudi Arabia, has appointed Abdullah Al Nahdi as chairman of its board of directors, placing the company's founder at the head of the board for a new term. The board took the decision at its first meeting of the term on the seventh of October and the company disclosed it to the Saudi Exchange the following day. Yaser Binmahfouz was appointed vice chairman.
The board also set its committee structure for the term. Abdullatif Al Saif was named chairman of the audit committee, joined by Wael Eid and Waleed Tamirek as members, for a new four-year term beginning on the fifth of October. A remuneration and nomination committee was constituted with Junaid Bajwa, Assaf Al Qurashi and Waleed Bahamdan. The board additionally formed a digital transformation and cybersecurity committee, and named Fahad Alhaidari as board secretary. The disclosure named no executive and carried no quotation.
Abdullah Al Nahdi founded the business that became Nahdi Medical, beginning with two pharmacies in Jeddah in 1986 and building it into the dominant retail pharmacy network in the Kingdom. He served as vice chairman of the board before this appointment, and is also founder and chairman of the Al Nahdi Family Office, established in 2019. His move from vice chairman to chairman consolidates founding-family control of the board at the start of a four-year cycle.
Nahdi Medical is listed on the Saudi Exchange under code 4164 and operates a nationwide network of retail pharmacies alongside a growing e-commerce and digital health business. The company was among the larger Saudi consumer listings of recent years and competes in a pharmacy retail market that has consolidated steadily as regulation, insurance penetration and digital prescription services have raised the cost of operating at small scale.
The composition tells the more useful story. Constituting a dedicated digital transformation and cybersecurity committee at board level, rather than leaving the subject inside audit or risk, signals that the board treats the digital channel as a strategic exposure rather than an operational one, which is consistent with a pharmacy retailer whose growth is migrating online and whose customer data obligations are rising under Saudi data protection rules. The appointment of the founder as chairman for a full four-year term, with the audit committee chair renewed in parallel, points to continuity rather than to a change of direction. For investors the question is whether a founder-led board accelerates or slows the capital decisions that digital expansion requires, and the first evidence of that will be the company's capital expenditure guidance for the coming financial year.
